| Genotype | Adjusted HR (95% CI) | P for interaction |
---|
Myocardial infarction |
---|
 rs731236 (TaqI) | GG / AA | 0.92 (0.74, 1.15) | 0.91 (0.79, 1.06) | 0.255 |
 rs7975232 (ApaI) | AA / CC | 0.86 (0.73, 1.01) | 0.94 (0.77, 1.14) | 0.776 |
 rs1544410 (BsmI) | TT / CC | 0.91 (0.73, 1.13) | 0.90 (0.78, 1.05) | 0.311 |
 rs2228570 (FokI) | GG / AA | 0.76 (0.66, 0.88) | 0.83 (0.66, 1.03) | 0.042 |
Stroke |
 rs731236 (TaqI) | GG / AA | 0.59 (0.39, 0.87) | 0.92 (0.72, 1.18) | 0.167 |
 rs7975232 (ApaI) | AA / CC | 0.57 (0.43, 0.75) | 0.90 (0.66, 1.23) | 0.304 |
 rs1544410 (BsmI) | TT / CC | 0.55 (0.38, 0.80) | 0.92 (0.72, 1.18) | 0.129 |
 rs2228570 (FokI) | GG / AA | 0.70 (0.55, 0.90) | 0.66 (0.44, 0.98) | 0.033 |
- Bold indicates statistically significant (PÂ <Â 0.05)
- HR  hazard ratio, CI  confidence interval, CVD  cardiovascular disease. Cox models were adjusted for sex (female/male), age (continuous), ethnicity (Whites/non-Whites), income (< £18,000/£18,000–30,999/£31,000–51,999/£52,000–100,000/ > £100,000), smoking habits (never/former/current), drinking habits (never/former/current), BMI (continuous), systolic BP (continuous), total cholesterol (continuous), high-density lipoprotein (continuous), serum creatinine (continuous), and the use of vitamin D supplement (yes/no), antihypertensive drugs (yes/no), lipid-regulating drugs (yes/no), and statins (yes/no). HR indicated the risk for per one unit increment in serum 25(OH)D concentration